For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 100,889 | 103,649* | 97,219 | 99,236 |
| General and administrative | 24,387 | 20,009* | 16,673 | 16,555 |
| Total operating expenses | 125,276 | 123,658 | 113,892 | 115,791 |
| Loss from operations | -125,276 | -123,658* | -113,892 | -115,791 |
| Interest income | 8,757 | 7,208* | 8,476 | 6,625 |
| Interest expense | 4,202 | 1,695* | 2,904 | 94 |
| Other income (expense), net | -133 | 280* | 279 | -1,597 |
| Total other income (expense), net | 4,422 | 5,793* | 5,851 | 4,934 |
| Net loss | -120,854 | -117,866* | -108,041 | -110,857 |
| Unrealized gains on marketable securities, net | -612 | 87* | 244 | 11 |
| Comprehensive loss | -121,466 | -117,780 | -107,797 | -110,846 |
| Basic EPS | -0.73 | -0.868* | -0.76 | -0.97 |
| Diluted EPS | -0.73 | -0.868* | -0.76 | -0.97 |
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)